10,685 Shares in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Purchased by Norden Group LLC

Norden Group LLC acquired a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,685 shares of the company’s stock, valued at approximately $59,000.

Several other institutional investors have also modified their holdings of VTYX. Tower Research Capital LLC TRC lifted its position in Ventyx Biosciences by 1,424.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 19,927 shares of the company’s stock worth $49,000 after buying an additional 18,620 shares during the last quarter. Federated Hermes Inc. bought a new stake in shares of Ventyx Biosciences in the 4th quarter worth about $50,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Ventyx Biosciences by 66.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,385 shares of the company’s stock worth $63,000 after acquiring an additional 4,553 shares during the last quarter. Aigen Investment Management LP purchased a new position in shares of Ventyx Biosciences during the 4th quarter worth about $65,000. Finally, Jump Financial LLC bought a new position in Ventyx Biosciences during the 4th quarter valued at about $72,000. 97.88% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on VTYX. HC Wainwright restated a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a research report on Thursday, June 13th. Oppenheimer cut their price objective on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, June 6th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $15.75.

Ventyx Biosciences Trading Up 3.6 %

Shares of VTYX stock opened at $2.56 on Monday. Ventyx Biosciences, Inc. has a twelve month low of $1.87 and a twelve month high of $38.20. The stock has a fifty day simple moving average of $3.54 and a two-hundred day simple moving average of $4.15. The stock has a market capitalization of $180.48 million, a price-to-earnings ratio of -0.79 and a beta of 0.39.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.05. During the same quarter in the previous year, the business earned ($0.68) earnings per share. Research analysts predict that Ventyx Biosciences, Inc. will post -2.31 EPS for the current fiscal year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.